Theranostic nanocells for simultaneous imaging and photodynamic therapy of pancreatic cancer

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7551, Issue , 2010, Pages

  Spring, Bryan ^a   Mai, Zhiming ^a   Rai, Prakash ^a   Chang, Sung ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti VEGF therapy; Liposomes; Nanocell; Nanoparticles; Pancreatic cancer; Photodynamic therapy

Indexed keywords

ANTI-VEGF THERAPY; AVASTIN; COMBINATION THERAPY; INTRACELLULAR DELIVERY; MOUSE MODELS; MULTIPLE IMAGING; NANOCELL; NANOCELLS; ORTHOTOPIC; PANCREATIC CANCERS; POLYMER NANOPARTICLES; SIMULTANEOUS IMAGING; SURVIVAL RATE; THERAPEUTIC AGENTS; TREATMENT OUTCOMES; TREATMENT RESPONSE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANTIBODIES; DRUG THERAPY; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; OPTICAL MATERIALS; PHOSPHOLIPIDS; PHOTOSENSITIZERS; PLASMONS; TUMORS;

PHOTODYNAMIC THERAPY;

EID: 77951614436     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.843725     Document Type: Conference Paper

References (48)

1. Banerjee, H.N. & Verma, M. Application of nanotechnology in cancer. Technol Cancer Res Treat 7, 149-154 (2008).
2. Farokhzad, O.C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103, 6315-6320 (2006).
3. Farokhzad, O.C. & Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58, 1456-1459 (2006).
4. Hartman, K.B., Wilson, L.J. & Rosenblum, M.G. Detecting and treating cancer with nanotechnology. Mol Diagn Ther 12, 1-14 (2008).
5. Heath, J.R. & Davis, M.E. Nanotechnology and cancer. Annu Rev Med 59, 251-265 (2008).
6. Jain, K.K. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat 4, 407-416 (2005).
7. Kawasaki, E.S. & Player, A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1, 101-109 (2005).
8. Pierotti, M.A., Lombardo, C. & Rosano, C. Nanotechnology: going small for a giant leap in cancer diagnostics and therapeutics. Tumori 94, 191-196 (2008). (Pubitemid 351838825)
9. Sengupta, S. & Sasisekharan, R. Exploiting nanotechnology to target cancer. Br J Cancer 96, 1315-1319 (2007).
10. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J Clin 58, 71-96 (2008).
11. Bramhall, S.R. et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82, 111-115 (1995).
12. Bramhall, S.R. & Neoptolemos, J.P. Advances in diagnosis and treatment of pancreatic cancer. Gastroenterologist 3, 301-310 (1995).
13. Ayaru, L., Bown, S.G. & Pereira, S.P. Photodynamic therapy for pancreatic and biliary tract carcinoma. Int J Gastrointest Cancer 35, 1-13 (2005). (Pubitemid 40458575)
14. Bown, S.G. et al. Photodynamic therapy for cancer of the pancreas. Gut 50, 549-557 (2002).
15. Duska, L.R., Hamblin, M.R., Miller, J.L. & Hasan, T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst 91, 1557-1563 (1999). (Pubitemid 29457960)
16. Kessel, D. Combination therapy involving photosensitizing agents. J Photochem Photobiol B 12, 203-204 (1992).
17. Kessel, D. Modes of resistance to antitumor agents. In Vivo 8, 829-834 (1994).
18. Kessel, D., Beck, W.T., Kukuruga, D. & Schulz, V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res 51, 4665-4670 (1991).
19. Kessel, D. & Erickson, C. Porphyrin photosensitization of multi-drug resistant cell types. Photochem Photobiol 55, 397-399 (1992).
20. Kessel, D. & Sun, H.H. Enhanced responsiveness to photodynamic therapy-induced apoptosis after mitochondrial DNA depletion. Photochem Photobiol 70, 937-940 (1999). (Pubitemid 129548340)
21. Kessel, D. & Woodburn, K. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitising agent. Br J Cancer 71, 306-310 (1995).
22. Dougherty, T.J. et al. Photodynamic therapy. J Natl Cancer Inst 90, 889-905 (1998).
23. Hasan, T., Ortel, B., Moor, A.C.E. & Pogue, B.W. in Cancer Medicine (ed. H. Frei) 605-622 (BC Dekker, Inc, New York, NY USA; 2003).
24. Hasan, T., Ortel, B., Solban, N. & Pogue, B. in Cancer Medicine, Edn. 7th. (eds. D.W. Kufe et al.) 537-548 (B.C. Decker, Inc., Hamilton, Ontario; 2006).
25. Itakura, J., Ishiwata, T., Shen, B., Kornmann, M. & Korc, M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85, 27-34 (2000).
26. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005).
27. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3, 4-10 (2005). (Pubitemid 41680947)
28. Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl 3, 11-16 (2005). (Pubitemid 41680948)
29. Bhuvaneswari, R., Gan, Y.Y., Yee, K.K., Soo, K.C. & Olivo, M. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma. Int J Mol Med 20, 421-428 (2007).
30. Bhuvaneswari, R., Yuen, G.Y., Chee, S.K. & Olivo, M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem Photobiol Sci 6, 1275-1283 (2007). (Pubitemid 350191102)
31. Ferrario, A. & Gomer, C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 25, 251-259 (2006). (Pubitemid 43341245)
32. Jiang, F. et al. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem Photobiol 84, 128-137 (2008). (Pubitemid 350265084)
33. Kosharskyy, B. et al. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 66, 10953-10958 (2006). (Pubitemid 44876994)
34. Jordan, B.F. et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7, 475-485 (2005).
35. Channual, J. et al. Vascular effects of photodynamic and pulsed dye laser therapy protocols. Lasers Surg Med 40, 644-650 (2008).
36. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3, 28-30 (2002).
37. Bevacizumab (Avastin) for metastic breast cancer. Med Lett Drugs Ther 50, 42-43 (2008).
38. Ferrara, N., Hillan, K.J. & Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333, 328-335 (2005).
39. Nalluri, S.R., Chu, D., Keresztes, R., Zhu, X. & Wu, S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. Jama 300, 2277-2285 (2008).
40. Sengupta, S. et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005). (Pubitemid 41112931)
41. Bechet, D. et al. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 26, 612-621 (2008).
42. Konan, Y.N., Berton, M., Gurny, R. & Allemann, E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm Sci 18, 241-249 (2003). (Pubitemid 36349275)
43. Konan, Y.N., Chevallier, J., Gurny, R. & Allemann, E. Encapsulation of p-THPP into nanoparticles: cellular uptake, subcellular localization and effect of serum on photodynamic activity. Photochem Photobiol 77, 638-644 (2003).
44. Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007). (Pubitemid 47268059)
45. Gerber, H.P. et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954-958 (2002).
46. Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P. & Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1, 193-202 (2002). (Pubitemid 41039165)
47. Santos, S.C. & Dias, S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103, 3883-3889 (2004).
48. von Marschall, Z. et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119, 1358-1372 (2000).